AKT1 and breast carcinoma: A previous study showed that combination treatment in PIK3CA-mutant HER2+ breast cancer cells using PI3K/Akt inhibitors and and anti HER2 lapatinib, increase sensitivity of lapatinib (Fujimoto et al., 2020).